Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TEKAMLO

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

Standard Dose
EQ 150MG BASE;EQ 5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TEKAMLO is listed in Drugs@FDA under application 022545 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE Form and strength TABLET;ORAL - EQ 150MG BASE;EQ 5MG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2016-11-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview TEKAMLO is listed in Drugs@FDA under application 022545 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE Form and strength TABLET;ORAL - EQ 150MG BASE;EQ 5MG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2016-11-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE) | Drug Monograph | MedicHelpline